Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
Background & Objectives: Trastuzumab and Idarubicin (4-methyl-daunorubicin) are two anti-neoplasmic agents that are widely used in cancer therapy. Idarubicin is more lipophilic than its parent drugs such as daunorubicin, therefore it is absorbed more efficiently by the target cells. The main aim of...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Fasa University of Medical Sciences
2017-11-01
|
| Col·lecció: | Journal of Advanced Biomedical Sciences |
| Matèries: | |
| Accés en línia: | http://jabs.fums.ac.ir/article-1-1270-en.pdf |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|